3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Classical hematology
2
Tumor-Agnostic
1
Thoracic
1
Sarcoma
1
Plasma cell
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Thrombosis
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
89
Capecitabine
88
Trastuzumab
81
Docetaxel
81
Paclitaxel
65
Epirubicin
57
pyrotinib
55
Tamoxifen
54
Letrozole
53
Fulvestrant
49
Vinorelbine
43
Carboplatin
43
Doxorubicin
41
Radiotherapy
33
Anastrozole
32
exemestane
31
Neoadjuvant Therapy
29
palbociclib
27
Drug Therapy
27
Fluorouracil
24
Bevacizumab
24
pertuzumab
23
Cisplatin
23
eribulin
22
Exercise
21
130-nm albumin-bound paclitaxel
21
Goserelin
20
Gemcitabine
20
Chemotherapy, Adjuvant
19
Albumin-Bound Paclitaxel
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Rivaroxaban
×
Breast
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled